Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30498935 | 1.00 | NAPRT (0.57) | NAPRTALDH1A1L3MBTL1KDM4ERAB9A | |
| Hydrochloric Acid SCHEMBL29136849 | 0.98 | NAPRT (0.55) | NAPRTALDH1A1L3MBTL1KDM4ERAB9A | |
| Hydrochloric Acid SCHEMBL19211717 | 0.98 | NAPRT (0.55) | NAPRTALDH1A1L3MBTL1KDM4ERAB9A | |
| Hydrochloric Acid SCHEMBL28556626 | 0.98 | NAPRT (0.55) | NAPRTALDH1A1L3MBTL1KDM4ERAB9A | |
| SCHEMBL29268395 | 0.83 | NAPRT (0.52) | NAPRTALDH1A1L3MBTL1KDM4EKEAP1 | |
| SCHEMBL12077955 | 0.82 | NAPRT (0.50) | NAPRTALDH1A1L3MBTL1KEAP1NFE2L2 | |
| SCHEMBL9954565 | 0.82 | NAPRT (0.50) | NAPRTALDH1A1L3MBTL1KEAP1NFE2L2 | |
| SCHEMBL30096931 | 0.81 | NAPRT (0.53) | NAPRTALDH1A1L3MBTL1KDM4EKEAP1 | |
| SCHEMBL27973675 | 0.81 | NAPRT (0.53) | NAPRTALDH1A1L3MBTL1KDM4ERAB9A | |
| SCHEMBL9959448 | 0.80 | CA12 (0.56) | NAPRTL3MBTL1KEAP1NFE2L2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023191400-A1 | ETHYL PIPERIDINE TRIAZOLO TRIAZINE DERIVATIVES, SYNTHESIS METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME FOR PREVENTION OR TREATMENT OF CANCER | 에이치케이이노엔 주식회사 | 2023-10-05 | — | — | WO | claimed |
| WO-2023191400-A1 | ETHYL PIPERIDINE TRIAZOLO TRIAZINE DERIVATIVES, SYNTHESIS METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME FOR PREVENTION OR TREATMENT OF CANCER | 에이치케이이노엔 주식회사 | 2023-10-05 | — | — | WO | disclosed |
| US-20220274968-A1 | Oxazole And Oxadiazole Derivatives Useful As Agonists Of Free Fatty Acid Receptor 1 | GBIOTECH S.À.R.L. (CH) | 2022-09-01 | — | — | US | disclosed |
| US-20200317666-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2020-10-08 | — | — | US | disclosed |
| US-20200317666-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2020-10-08 | — | — | US | disclosed |
| US-10717733-B2 | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof | PHARMAXIS LTD. (AU) | 2020-07-21 | — | — | US | disclosed |
| US-10717733-B2 | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof | PHARMAXIS LTD. (AU) | 2020-07-21 | — | — | US | disclosed |
| US-20190040007-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2019-02-07 | — | — | US | disclosed |
| US-20190040007-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2019-02-07 | — | — | US | disclosed |
| EP-3414244-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | Pharmaxis Ltd. (AU) | 2018-12-19 | — | — | EP | disclosed |
| CN-101754759-A | Quinoline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORP | 2010-06-23 | — | — | CN | disclosed |
| EP-2154965-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | Glaxosmithkline LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-2150255-A1 | QUINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS | Smithkline Beecham Corporation (US) | 2010-02-10 | — | — | EP | disclosed |
| WO-2009133127-A1 | FUSED BICYCLIC COMPOUNDS AND USE THEREOF AS PI3K INHIBITORS | MERCK SERONO S.A. (CH) | 2009-11-05 | — | — | WO | disclosed |
| US-20090258861-A1 | Tetrahydronaphthyridine Derivatives | LUNN GRAHAM | 2009-10-15 | — | — | US | disclosed |
| EP-1831198-B1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008150827-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008141065-A1 | QUINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-20 | — | — | WO | disclosed |
| EP-1831198-A1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067446-A1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717733-B2 | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof | IDO1, IDO2, INMT | NAPRT 500/4885ALDH1A1 326/4885L3MBTL1 1096/4885 |
| US-20090258861-A1 | Tetrahydronaphthyridine Derivatives | HRH4, HRH3, HRH1 | NAPRT 1233/4885ALDH1A1 538/4885L3MBTL1 2662/4885 |
| US-20190040007-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | IDO1, IDO2, INMT | NAPRT 500/4885ALDH1A1 326/4885L3MBTL1 1096/4885 |
| US-20200317666-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | IDO1, IDO2, INMT | NAPRT 500/4885ALDH1A1 326/4885L3MBTL1 1096/4885 |
| US-20220274968-A1 | Oxazole And Oxadiazole Derivatives Useful As Agonists Of Free Fatty Acid Receptor 1 | FFAR2, FFAR1, FFAR3 | NAPRT 2049/4885ALDH1A1 1197/4885L3MBTL1 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.